Please try another search
Symbol | Exchange | Currency | ||
---|---|---|---|---|
FGEN | NASDAQ | USD | Real-time | |
FGEN | Mexico | MXN | Delayed | |
1FG | Frankfurt | EUR | Delayed |
FibroGen, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. Its lead product candidates are Pamrevlumab, a human monoclonal antibody targeting connective tissue growth factor that is in Phase III clinical development for the treatment of locally advanced pancreatic cancer; and Roxadustat, an oral small molecule inhibitor of hypoxia-inducible factor prolyl hydroxylase activity, which has completed Phase III clinical development for the treatment of anemia in chronic kidney disease in China, Europe, Japan, and other countries, as well as in Phase III clinical development for anemia related with myelodysplastic syndromes. The company has collaboration agreements with Astellas Pharma Inc. and AstraZeneca AB. FibroGen, Inc. was incorporated in 1993 and is headquartered in San Francisco, California.
Name | Age | Since | Title |
---|---|---|---|
James A. Schoeneck | 64 | 2010 | Independent Chairman of the Board |
George R. Martin | - | - | Chairman of Scientific Advisory Board |
Jeffrey W. Henderson | 58 | 2015 | Independent Director |
Suzanne Blaug | 65 | 2019 | Independent Director |
Aoife M. Brennan | 47 | 2020 | Independent Director |
Gerald Lema | 62 | 2017 | Independent Director |
Benjamin F. Cravatt | 53 | 2020 | Independent Director |
Jeffrey L. Edwards | 62 | 2015 | Independent Director |
Maykin Ho | 70 | 2018 | Independent Director |
Thane Wettig | 58 | 2020 | CEO & Director |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review